Gilde Healthcare

Gilde Healthcare runs a Frankfurt office that extends the broader Benelux firm’s reach into the German-speaking healthcare market. The team focuses on established healthtech and medical device companies, with the stated aim of optimizing care delivery rather than betting on early-stage discovery. Despite being categorized as private equity, Gilde Healthcare is well-known across European healthcare investing for blending growth-stage venture and PE strategies. AI is not the headline thesis — the focus is on operational maturity in healthtech and devices.

The Frankfurt arm invests at Series B, Series C, and growth stages with check sizes between $5M and $25M. That makes it a candidate for upsizing existing rounds, leading later-stage growth financings, or backing companies with revenue and a clear path to scale. European founders, particularly those with traction in DACH and Benelux markets, are the natural target.

Founders should approach Gilde Healthcare when they have meaningful commercial traction, a defensible product in healthcare software or devices, and an ambition to consolidate or expand across European geographies. Pre-revenue companies, science-stage biotech, and pure US-focused plays are unlikely to be the right fit. The team will look closely at unit economics, regulatory positioning across multiple European markets, and the management team’s ability to execute a growth plan. Treat this as institutional growth capital rather than a hands-on early-stage partner.